Literature DB >> 26364961

Prothymosin-alpha preconditioning activates TLR4-TRIF signaling to induce protection of ischemic retina.

Sebok Kumar Halder1, Hayato Matsunaga1, Ken J Ishii2, Hiroshi Ueda1.   

Abstract

Prothymosin-alpha protects the brain and retina from ischemic damage. Although prothymosin-alpha contributes to toll-like receptor (TLR4)-mediated immnunopotentiation against viral infection, the beneficial effects of prothymosin-alpha-TLR4 signaling in protecting against ischemia remain to be elucidated. In this study, intravitreal administration of prothymosin-alpha 48 h before induction of retinal ischemia prevented retinal cellular damage as evaluated by histology, and retinal functional deficits as evaluated by electroretinography. Prothymosin-alpha preconditioning completely prevented the ischemia-induced loss of ganglion cells with partial survival of bipolar and photoreceptor cells, but not amacrine cells, in immunohistochemistry experiments. Prothymosin-alpha treatment in the absence of ischemia caused mild activation, proliferation, and migration of retinal microglia, whereas the ischemia-induced microglial activation was inhibited by prothymosin-alpha preconditioning. All these preventive effects of prothymosin-alpha preconditioning were abolished in TLR4 knock-out mice and by pre-treatments with anti-TLR4 antibodies or minocycline, a microglial inhibitor. Prothymosin-alpha preconditioning inhibited the retinal ischemia-induced up-regulation of TLR4-related injury genes, and increased expression of TLR4-related protective genes. Furthermore, the prothymosin-alpha preconditioning-induced prevention of retinal ischemic damage was abolished in TIR-domain-containing adapter-inducing interferon-β knock-out mice, but not in myeloid differentiation primary response gene 88 knock-out mice. Taken together, the results of this study suggest that prothymosin-alpha preconditioning selectively drives TLR4-TIR-domain-containing adapter-inducing interferon-β signaling and microglia in the prevention of retinal ischemic damage. We propose the following mechanism for prothymosin-alpha (ProTα) preconditioning-induced retinal prevention against ischemia: ProTα preconditioning-induced prevention of retinal ischemic damage is mediated by selective activation of the TIR-domain-containing adapter-inducing interferon-β (TRIF)- interferon regulatory factor 3 (IRF3) pathway downstream of toll-like receptor 4 (TLR4) in microglia, resulting in up-regulation of TRIF-IRF3-dependent protective genes and down-regulation of myeloid differentiation primary response gene 88 (MyD88)-Nuclear factor (NF)κB-dependent injury genes. Detailed investigations would be helpful to test the efficacy of ProTα as a therapeutic agent for the prevention of ischemic disorders.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  TLR4; TRIF; ischemia; microglia; neuroprotection; prothymosin-alpha

Mesh:

Substances:

Year:  2015        PMID: 26364961     DOI: 10.1111/jnc.13356

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

1.  Adaptive Plasticity in the Retina: Protection Against Acute Injury and Neurodegenerative Disease by Conditioning Stimuli.

Authors:  Jeffrey M Gidday
Journal:  Cond Med       Date:  2018-02-15

2.  Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma.

Authors:  Chaobin Lin; Fujin Wu; Tongmei Zheng; Xiuchun Wang; Yiwei Chen; Xiaomin Wu
Journal:  Eye (Lond)       Date:  2018-12-18       Impact factor: 3.775

3.  Hexapeptide derived from prothymosin alpha attenuates cisplatin-induced acute kidney injury.

Authors:  Kenta Torigoe; Yoko Obata; Miki Torigoe; Satoru Oka; Kazuo Yamamoto; Takehiko Koji; Hiroshi Ueda; Hiroshi Mukae; Tomoya Nishino
Journal:  Clin Exp Nephrol       Date:  2020-01-07       Impact factor: 2.801

4.  Deletion of Nuclear Localizing Signal Attenuates Proinflammatory Activity of Prothymosin-Alpha and Enhances Its Neuroprotective Effect on Transient Ischemic Stroke.

Authors:  Liang-Chao Wang; Chao-Liang Wu; Ya-Yun Cheng; Kuen-Jer Tsai
Journal:  Mol Neurobiol       Date:  2016-01-09       Impact factor: 5.590

5.  Identification of ribosomal protein L9 as a novel regulator of proinflammatory damage-associated molecular pattern molecules.

Authors:  Masahiro Watanabe; Takao Toyomura; Hidenori Wake; Takashi Nishinaka; Omer Faruk Hatipoglu; Hideo Takahashi; Masahiro Nishibori; Shuji Mori
Journal:  Mol Biol Rep       Date:  2022-01-21       Impact factor: 2.316

6.  Low-dose minocycline mediated neuroprotection on retinal ischemia-reperfusion injury of mice.

Authors:  Ruojing Huang; Shaomin Liang; Lyujie Fang; Min Wu; Huanhuan Cheng; Xuesong Mi; Yong Ding
Journal:  Mol Vis       Date:  2018-05-18       Impact factor: 2.367

7.  S100B immunization triggers NFκB and complement activation in an autoimmune glaucoma model.

Authors:  Sabrina Reinehr; Jacqueline Reinhard; Marcel Gandej; Ivo Gottschalk; Gesa Stute; Andreas Faissner; H Burkhard Dick; Stephanie C Joachim
Journal:  Sci Rep       Date:  2018-06-29       Impact factor: 4.379

Review 8.  Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders.

Authors:  Rezan Ashayeri Ahmadabad; Zahra Mirzaasgari; Ali Gorji; Maryam Khaleghi Ghadiri
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

9.  Wogonin prevents TLR4-NF-κB-medicated neuro-inflammation and improves retinal ganglion cells survival in retina after optic nerve crush.

Authors:  Yue Xu; Boyu Yang; Yaguang Hu; Lin Lu; Xi Lu; Jiawei Wang; Fan Xu; Shanshan Yu; Jingjing Huang; Xiaoling Liang
Journal:  Oncotarget       Date:  2016-11-08

Review 10.  Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Authors:  P Samara; K Ioannou; O E Tsitsilonis
Journal:  Vitam Horm       Date:  2016-05-27       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.